# A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors

> **NCT00908908** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 6 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** eribulin

## Key facts

- **NCT ID:** NCT00908908
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2012-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908908, "A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00908908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*